Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Triple Negative Breast Neoplasms × Atorvastatin × Clear all

Phase

Status

Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Polycystic Ovary Syndrome 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Waldenstrom Macroglobulinemia 1 Venous Thrombosis 1 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Ototoxicity 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Prolymphocytic 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Kidney Neoplasms 1 Inflammation 1 Hodgkin Disease 1 Hemangioma, Cavernous, Central Nervous System 1 Heart Failure 1

Interventions

Carboplatin 41 Paclitaxel 40 pembrolizumab 38 Cyclophosphamide 23 Gemcitabine 21 130-nm albumin-bound paclitaxel 21 Doxorubicin 18 Cisplatin 18 Albumin-Bound Paclitaxel 18 atezolizumab 16 Taxes 15 Capecitabine 13 veliparib 10 Nivolumab 9 Docetaxel 9 Bevacizumab 9 olaparib 8 liposomal doxorubicin 7 Everolimus 7 spartalizumab 6 durvalumab 6 Epirubicin 6 trametinib 5 pegfilgrastim 5 eribulin 5 Irinotecan 5 Filgrastim 5 iniparib 4 binimetinib 4 apatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03358017 2023-10-19

YAPPETIZER

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡